Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Recently identified and potential targets for colon cancer treatment.

Lea MA.

Future Oncol. 2010 Jun;6(6):993-1002. doi: 10.2217/fon.10.53. Review.

PMID:
20528236
2.

Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: a Bcl-2- and superoxide dismutase 2-dependent mechanism.

Priego S, Feddi F, Ferrer P, Mena S, Benlloch M, Ortega A, Carretero J, Obrador E, Asensi M, Estrela JM.

Mol Cancer Ther. 2008 Oct;7(10):3330-42. doi: 10.1158/1535-7163.MCT-08-0363.

3.

The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.

Na YS, Jung KA, Kim SM, Hong YS, Ryu MH, Jang SJ, Moon DH, Cho DH, Kim JC, Lee JS, Kim TW.

Cancer Chemother Pharmacol. 2011 Aug;68(2):389-98. doi: 10.1007/s00280-010-1495-6. Epub 2010 Nov 3.

PMID:
21046105
4.

Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.

Bishton M, Kenealy M, Johnstone R, Rasheed W, Prince HM.

Expert Rev Anticancer Ther. 2007 Oct;7(10):1439-49. Review.

PMID:
17944568
5.

Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.

Na YS, Kim SM, Jung KA, Yang SJ, Hong YS, Ryu MH, Ro S, Cho DH, Kim JC, Jin DH, Lee JS, Kim TW.

Oncol Rep. 2010 Dec;24(6):1509-14.

PMID:
21042746
6.
7.

The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.

Flanigan SA, Pitts TM, Eckhardt SG, Tentler JJ, Tan AC, Thorburn A, Leong S.

Clin Cancer Res. 2010 Nov 15;16(22):5436-46. doi: 10.1158/1078-0432.CCR-10-2054. Epub 2010 Oct 13.

8.

Conditionally replicative adenovirus-based mda-7/IL-24 expression enhances sensitivity of colon cancer cells to 5-fluorouracil and doxorubicin.

Xu J, Mo Y, Wang X, Liu J, Zhang X, Wang J, Hu L, Yang C, Chen L, Wang Y.

J Gastroenterol. 2013 Feb;48(2):203-13. doi: 10.1007/s00535-012-0623-y. Epub 2012 Jul 21.

PMID:
22820863
9.

Epigenetic modulation and attacking the hedgehog pathway: potentially synergistic therapeutic targets for pancreatic cancer.

Freeman JW, Wang Y, Giles FJ.

Cancer Biol Ther. 2009 Jul;8(14):1340-2. Epub 2009 Jul 17. No abstract available.

PMID:
19440037
10.
11.

Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma.

Weirauch U, Beckmann N, Thomas M, Grünweller A, Huber K, Bracher F, Hartmann RK, Aigner A.

Neoplasia. 2013 Jul;15(7):783-94.

12.

Integration of novel agents in the treatment of colorectal cancer.

Iqbal S, Lenz HJ.

Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. Review.

PMID:
15309512
13.

Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.

Pencreach E, Guérin E, Nicolet C, Lelong-Rebel I, Voegeli AC, Oudet P, Larsen AK, Gaub MP, Guenot D.

Clin Cancer Res. 2009 Feb 15;15(4):1297-307. doi: 10.1158/1078-0432.CCR-08-0889. Epub 2009 Feb 3.

14.

DNA demethylating agents and epigenetic therapy of cancer.

Mani S, Herceg Z.

Adv Genet. 2010;70:327-40. doi: 10.1016/B978-0-12-380866-0.60012-5. Review.

PMID:
20920754
15.

Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.

Houghton JA, Cheshire PJ, Hallman JD 2nd, Lutz L, Luo X, Li Y, Houghton PJ.

Clin Cancer Res. 1996 Jan;2(1):107-18.

16.

Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.

Paillas S, Boissière F, Bibeau F, Denouel A, Mollevi C, Causse A, Denis V, Vezzio-Vié N, Marzi L, Cortijo C, Ait-Arsa I, Askari N, Pourquier P, Martineau P, Del Rio M, Gongora C.

Cancer Res. 2011 Feb 1;71(3):1041-9. doi: 10.1158/0008-5472.CAN-10-2726. Epub 2010 Dec 15.

17.

High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.

Rasmussen MH, Jensen NF, Tarpgaard LS, Qvortrup C, Rømer MU, Stenvang J, Hansen TP, Christensen LL, Lindebjerg J, Hansen F, Jensen BV, Hansen TF, Pfeiffer P, Brünner N, Ørntoft TF, Andersen CL.

Mol Oncol. 2013 Jun;7(3):637-46. doi: 10.1016/j.molonc.2013.02.016. Epub 2013 Feb 28.

18.

New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.

Cang S, Ma Y, Liu D.

J Hematol Oncol. 2009 Jun 1;2:22. doi: 10.1186/1756-8722-2-22. Review.

19.

Update on HER-kinase-directed therapy in prostate cancer.

Gross ME, Jo S, Agus DB.

Clin Adv Hematol Oncol. 2004 Jan;2(1):53-6, 64. Review.

PMID:
16163160
20.

Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies.

Crea F, Nobili S, Paolicchi E, Perrone G, Napoli C, Landini I, Danesi R, Mini E.

Drug Resist Updat. 2011 Dec;14(6):280-96. doi: 10.1016/j.drup.2011.08.001. Epub 2011 Sep 28. Review.

PMID:
21955833
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk